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Abstract
Alzheimer disease is characterized by the accumulation of β-amyloid (Aβ) plaques and tau-laden neurofibrillary
tangles. Emerging studies suggest that in neurodegenerative diseases, aggregation of one protein species can
promote other proteinopathies and that inflammation plays an important role in this process. To study the
interplay between Aβ deposition, tau pathology, and microgliosis, we established a new AD transgenic mouse
model by crossing 5xfAD mice with Thy-Tau22 transgenic mice. The resulting ‘T5x’ mice exhibit a greater than
three-fold increase in misfolded and hyperphosphorylated tau and further substantiates the hypothesis that Aβ
accelerates tau pathology. Surprisingly, T5x mice exhibit a 40-50 % reduction in Aβ plaque load and insoluble Aβ
species when compared with aged-matched 5xfAD littermates. T5x mice exhibit significant changes in cytokine
production, an almost doubling of microglial number, and a dramatic shift in microglia activation state.
Furthermore, T5x microglia exhibit increased phagocytic capacity that enhances the clearance of insoluble Aβ
and decreasing plaque load. Therefore, our results suggest that strategies to increase the phagocytic ability of
microglia can be employed to reduce Aβ and that tau-induced changes in microglial activation state can
promote the clearance of Aβ.
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Introduction
Alzheimer’s Disease (AD) is the leading cause of age-
related dementia, affecting over 5 million people in the
United States alone [5]. AD pathology is characterized
by two primary lesions: extracellular amyloid plaques
and intraneuronal tau-laden neurofibrillary tangles. The
mechanisms that drive AD remain unclear, but the
‘amyloid cascade hypothesis’ first proposed by Hardy
and Higgins posits that beta-amyloid (Aβ) accumulation
is the initiating factor in AD pathogenesis [8, 31, 33]. In-
creased deposition of Aβ, in turn, is thought to promote
the hyperphosphorylation of tau leading to neurofibril-
lary tangle (NFT) formation [2]. Together, Aβ and tau
pathologies disrupt critical biological functions such as
axonal transport and synaptic function and promote
neuroinflammation, ultimately leading to widespread
synaptic and neuronal loss [65, 83].
The role of neuroinflammation in the development
and progression of AD has been studied for several de-
cades [26, 27, 34]. However, the recent identification of
AD risk polymorphisms in several microglial-enriched
genes such as TREM2, MS4A, and CD33, has intensi-
fied this area of research [9, 15, 25, 28, 32, 42, 51, 86].
Microglia serve as one of the brain’s primary mecha-
nisms of Aβ clearance, but also play critical roles in
neuronal homeostasis and synaptic plasticity [63, 69, 76].
In response to Aβ, microglia increase their expression of
pro-inflammatory cytokines, which has been shown to
promote tau hyperphosphorylation and NFT pathology
[10, 49] and contribute to synaptic and neuronal dysfunc-
tion [3, 30, 69].
To better understand the role of microglia in the in-
teractions between Aβ and tau pathologies we crossed
two transgenic AD models, 5xfAD and Thy-Tau22
mice, to create a novel bigenic line termed ‘T5x’ mice.
5xfAD mice express three APP mutations (Swedish,
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Florida, London) and two PS1 mutations (M146L, L286V)
that are co-inherited and driven under control of the
neuronal-specific Thy1.2 promoter [61]. 5xfAD exhibit
intraneuronal Aβ accumulation beginning at 1.5 months,
amyloid plaque deposition and gliosis starting at 2 months,
synaptic loss by 6 months, and neuronal death beginning
at 9 months of age [22]. Amyloid deposition in these mice
is most prominent in the hippocampus, subiculum, deep
cortical layers, and the basal lateral amygdala. Increased
neuroinflammation and microglial activation have also
been shown to play an essential role in mediating disease
progression in this model [43]. Thus, 5xfAD mice provide
an aggressive amyloidogenic model that exhibit robust
AD-associated plaque pathology and microgliosis. In com-
parison, Thy-Tau22 mice express human four repeat tau
with two mutations (G272V, P301S) driven under the
Thy1.2 promoter and progressively develop hippocampal
hyperphosphorylated tau, neurofibrillary tangles, and glio-
sis [72]. Studies examining the effects of exercise, caffeine
and A2A receptor modulation in Thy-Tau22 mice suggest
important roles for microglia and neuroinflammatory re-
sponses in the accumulation of tau pathology [7, 44].
Interactions between Aβ and tau in mouse models were
first reported in two seminal studies in 2001 that clearly
demonstrated that Aβ accumulation could accelerate the
development of tau pathology [24, 47]. Subsequently, the
3xTg-AD model was generated and extended our under-
standing of the influence of Aβ on tau and was used to ex-
plore the role of microglial inflammation in this process
[39, 62]. Since then several other bigenic models have
been created and studies have continued to investigate the
effects of amyloid on tau and suggested that the amyloid
cascade follows a unidirectional pathway [18, 35, 71].
However, many of these models exhibit far less pathology
than occurs in human AD cases and thus more complex
interactions that might occur over decades in the hu-
man brain or at later stages of advanced disease may
not be faithfully recapitulated in many of these models
[85]. Furthermore, the potential role of inflammation in
these interactions between Aβ and tau remains greatly
understudied.
In the present study, we combined a model of Aβ ac-
cumulation (5xfAD mice) with a progressive model of
neurofibrillary tangle pathology (Thy-Tau22 mice). The
resulting ‘T5x’ mice were generated to provide insight
into the later stages of disease progression akin to that
observed in clinically-diagnosed AD patients and the
interactions and consequences of advanced amyloid path-
ology on tau and visa-versa. By comparing T5x bigenic
mice to their single transgenic littermates we have uncov-
ered potential new roles for tau in the modulation of Aβ
and neuroinflammatory response. Most notably, we iden-
tify and examine how amyloid and tau synergize to alter
microglial activity and promote Aβ clearance. Thus, these
data provide additional insight into the relationship be-
tween AD pathology and neuroinflammatory response
and suggest that tau can exhibit reciprocal interactions
with amyloid.
Material and Methods
Generation of T5x mice
Thy-Tau22 mice express human 4 repeat tau with two
frontotemporal dementia-associated point mutations
(G272V and P301S) under control of the neuronal driven
promoter Thy1.2 and are maintained on a C57Bl6/J back-
ground [72]. The 5xfAD mice used in this study are also
maintained on a congenic C57Bl6/J background and were
purchased from the Mutant Mouse Resource and Re-
search Center (MMRRC, stock# 034848-JAX). The 5xfAD
model co-expresses human amyloid precursor protein
(APP695) carrying the Swedish, Florida, and London mu-
tations and a human presenilin-1 (PS1) transgene carrying
the M146L and L286V mutations under the Thy-1 pro-
moter. Both APP and PS1 transgenes are co-integrated
and thus co-inherited. Heterozygous Thy-Tau22 and
5xfAD mice were crossed to create Thy-Tau22-5xfAD
(T5x) mice, as well as Thy-Tau22, 5xfAD, and WT litter-
mates that were genotyped via PCR amplification of
human tau, PS1, and APP transgenes. The number of
mice from each sex-balanced genotype was: WT (n = 8),
5x (n = 11), Tau (n = 14), and T5x (n = 9). All mice were
maintained on a purebred C57Bl/6 background and group
housed (2–4 mice/cage) on a 12 h/12 h light/dark cycle
with access to food and water ad libitum. All animal
procedures were performed in strict accordance to the
National Institutes of Health and University of California
Institutional Animal Care and Use Committee.
Tissue preparation and neuropathological analysis
Following behavioral testing, all mice were sedated with
euthasol and sacrificed by cardiac perfusion with 0.1 M
phosphate buffered saline (PBS). Brains were removed
and one hemisphere was snap frozen on dry ice while
the other hemisphere was postfixed in 4 % paraformal-
dehyde for 48 h then stored in PBS + 0.05 % sodium
azide. Fixed half-brains were placed in 30 % sucrose for
at least 48 h before being cut in the coronal plane
(40 μm sections) using a freezing sliding microtome.
Immunohistological staining
Brain sections were rinsed in PBS three times and blocked
in PBS + 0.05 % Triton-X with 5 % donkey or goat serum
for one hour. Primary antibodies used included: 6E10
(Covance; 1:500) and 82E1 (ABL America; 1:500) against
Aβ, total Tau (human +mouse; Dako; 1:1000), human tau
(HT7, ThermoFisher; 1:1000), phosho-tau epitopes AT8
(Pierce; 1:500) and PHF-1, and conformational tau epitope
MC-1 (generously provided by Peter Davies; 1:1000).
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Analysis of gliosis, phagocytosis, and dendritic architec-
ture utilized CD68 (Abcam; 1:200), IBA1 (Wako; 1:1000),
GFAP (Abcam; 1:1000), Beta3Tubullin (Covance; 1:1000).
Sections were incubated in primary antibodies at 4° Celsius
overnight. Sections were then washed three times with PBS
and incubated with appropriate Alexa fluor-conjugated sec-
ondary antibodies at room temperature for one hour. Sec-
tions were then rinsed three additional times, mounted on
slides and coverslipped with Fluoromount-G with DAPI.
Biochemical analysis
Hippocampus and cortex was microdissected from frozen
brains and processed to collect both soluble and insoluble
extracts. Briefly, microdissected tissue was homogenized
in TPER (ThermoFisher) and centrifuged at 12,000 RPM
for 15 min. Supernatant was collected as the soluble frac-
tion and the pellet was treated with 70 % formic acid and
spun down at 25,000 rpm. The resulting supernatant was
collected as the insoluble fraction. Insoluble protein sam-
ples were neutralized for Western blotting and further
precipitated with trichloroacetic acid (TCA) when probing
for insoluble tau. Protein samples were denatured at 95 °C
for 15 min before being loaded onto 4-20 % TGX precast
polyacrylamide gels (Bio-rad). Antibodies used for western
blotting include: HT7 (1:1000), PS199 (Abcam; 1:1000),
PS202 (Abcam; 1:1000), AT100 (ThermoFisher; 1:1000),
AT270 (ThermoFisher; 1:1000), PHF1 (1:1000), 6E10
(1:1000), GFAP (1:1000). Mesoscale Discovery immuno-
assay kits (Mesoscale Diagnostics) were used for cytokine
(K15048G) and Aβ38, 40, and 42 (K15199E) quantification
of cortical samples following the manufacturers protocols.
The proinflammatory MSD was able to detect levels of
that were within the standard curve, whereas brain levels
of IFN-γ, IL-12p70, CXCL1 and IL-4 were below the
threshold of detection.
Confocal microscopy and quantification
Equivalent brain sections were picked and immunofluor-
escent sections were imaged using Olympus FX1200
confocal microscope. Amyloid plaque burden identified by
82E1 were visualized through a Z-stack image taken
through the entire depth of the section at 1 μm intervals.
Confocal files were then rendered in 3D and analyzed by a
blinded observer using the volume function of IMARIS
software (Bitplane). Microglia and astrocyte quantification
by confocal microscopy was also analyzed using IMARIS.
Microglia number was quantified using IMARIS spot
function and process morphology was measured using
filament length and branching functions. Astrocyte
IMARIS quantification was performed using the volumet-
ric function. Microglia phagocytosis of Aβ was quantified
using a combined immunofluorescent staining of IBA1,
82E1, and CD68. High magnification Z-stack images were
taken of randomly selected plaques while being blinded to
IBA1 microglial staining. Quantification of internalized
Aβ was done according to previously described protocols
[40, 54]. To account for varying total microglia numbers
across images, the internalized Aβ index was normalized
to the number of microglia per image. Quantification of
neuronal degeneration was performed in equivalent hip-
pocampal brain sections using immunohistochemical la-
beling of Beta-III Tubulin (B3T). Four randomly selected
square sub-areas were selected in pyramidal, radiatum, or
molecular layers of hippocampus CA1 and quantified by
optical density using ImageJ.
Nanostring analysis
RNA was isolated from microdissected hippocampi of
WT, Thy-Tau22, 5xfAD, and T5x mice using RNeasy
Plus Universal Mini Kit (Qiagen). RNA samples were
run a custom Nanostring panel (Nanostring Technolo-
gies) examining mouse AD-linked genes. To evaluate
mouse amyloidogenesis, we compared levels of murine
RNA for genes APP, BACE1, BACE2, ADAM10, PSEN1,
and PSEN2.
Statistical analysis
Statistical analysis was performed using StatView software
(SAS Institute Inc.). Statistical comparisons between mul-
tiple groups were performed using ANOVA followed by
Fischer’s PLSD post-hoc tests. Error bars represent the
standard error of the mean. Groups were considered sta-
tistically significant when *p < 0.05 for both ANOVA and
posthoc analysis.
Results
Aβ pathology induces robust tau hyperphosphorylation
and neurofibrillary tangle formation in T5x mice
Brains of WT, Thy-Tau22, 5xfAD, and T5x mice
(7 months) were examined by immunocytochemistry to
assess accumulation of tau and beta-amyloid. Robust
accumulation of tau (green) and Aβ (red) plaques was
detected throughout the brain of T5x mice with extensive
extracellular amyloid plaque pathology and intraneuronal
tau accumulation observed within the hippocampus,
neocortex and amygdala (Fig. 1). Next, biochemical ap-
proaches were used to quantify changes in tau pathology
induced by Aβ accumulation. Soluble levels of total
human tau (HT7 antibody) were quantified in the hippo-
campus and cortex of 7-month old littermates of each
genotype (Fig. 2, Additional file 1: Figure S1). As expected,
human tau was detectable only in mice that expressed the
human tau transgene; Thy-Tau22 and T5x. Interestingly,
levels of the 60 kDa human tau species were not signifi-
cantly different between T5x and Thy-Tau22 littermates
in either the hippocampus (p = 0.33) or cortex (p = 0.13).
In contrast, the HT7 antibody also recognized a higher
molecular weight tau species (65 kDa) that exhibited
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marked increases in T5x versus Thy-Tau22 mice in
both the hippocampus (p = 0.0007; Fig. 2a) and cortex
(p = 0.01; Additional file 1: Figure S1A). The ratio of
the phosphorylated 65 kDa tau band to the unpho-
sphorylated 60 kDa tau band was also significantly
higher in T5x mice relative to Tau22 littermates in
hippocampus (p = 0.004; Additional file 2: Figure S2A)
and cortex (p = 0.001; Additional file 2: Figure S2A). Be-
cause the hyperphosphorylation of tau results in an
electrophoretic shift in migration, these data provide
evidence that Aβ accumulation leads to increased sol-
uble hyperphosphorylated tau in T5x mice.
To further characterize how Aβ alters tau hyperpho-
sphorylation, soluble hippocampal and cortical lysates were
probed for multiple pathological tau epitopes (i.e. AT100,
AT270, PHF-1). For many of the phospho-epitopes, two
bands were often detected, likely representing tau species
with varying degrees of hyperphosphorylation at multiple
sites. Quantification of these phospho-epitopes within both
the hippocampus and cortex, demonstrate that many
exhibit a 2–3 fold elevation in T5x mice compared to
Thy-Tau22 littermates (Fig. 2, Additional file 1: Figure
S1, p < 0.001). As tau becomes hyperphosphorylated, it
aggregates and becomes increasing insoluble. Therefore,
we examined whether insoluble tau was also increased
within T5x mice. While total levels of insoluble human
tau (HT7) were unchanged between T5x and Thy-Tau22
mice, T5x mice exhibited a dramatic increase in several
hyperphosphorylated insoluble tau species, as AT100,
AT270, and PHF1 levels were elevated 5–8 fold in T5x
mice compared to Thy-Tau22 littermates (Fig. 2, Additional
file 1: Figure S1, p < 0.001).
Increased tau hyperphosphorylation within T5x brain
was further confirmed immunohistochemically. The
brains of T5x mice exhibited increased numbers and
density of AT8, AT100, and PHF1 immunoreactive neu-
rons within both the hippocampus and cortex when
compared to Thy-Tau22 (Figs. 2c-d, Additional file 1:
Figure S1C-D). In AD, it is hypothesized that tau mis-
folds prior to hyperphosphorylation and this change can
be detected with the conformation-specific antibody
MC-1 [38]. Indeed, MC-1 immunoreactivity was more
prevalent in the brains of T5x versus Thy-Tau22 mice,
exhibiting a more than three-fold increase in the hippo-
campus and cortex (Figs. 2e-f, Additional file 1: Figure
S1E-F and 2B). Thus, consistent with previous reports, it
Fig. 1 T5x mice exhibit robust accumulation of both beta- amyloid and tau pathologies within the hippocampus, cortex, and amygdala. Tau
(Green; Dako total tau) and beta-amyloid (Red; 6E10) were examined by immunofluorescence and confocal microscopy in half brain coronal
sections, revealing appropriate labeling of Aβ plaques and/or tau-laden neurofibrillary tangles in the hippocampus and overlying cortex of each
genotype; WT (a), 5xfAD (b), Thy-Tau22 (c), T5x (d). Confocal settings were first established using T5x mice and then identical settings were used
for all genotypes. Higher power images of the CA1 region of the hippocampus and amygdala further demonstrate a lack of either pathology in
WT controls (e, i), Aβ pathology in 5xfAD mice (f, j), tau pathology in Thy-Tau22 mice (g, k), a combination of amyloid and tau pathology in T5x
(h, l). Scale Bar = 300 μm in (a-d), 50 μm in (e-g), and 100 μm in (i-k)
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Fig. 2 (See legend on next page.)
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appears that the presence of beta-amyloid pathology ac-
celerates the accumulation, misfolding, and hyperpho-
sphorylation of tau in T5x mice.
T5x mice exhibit differential levels of cytokines in brain
Cytokines have been implicated in the modulation of
microglia number and function in the presence of beta-
amyloid and tau pathologies. To determine the combined
effects of tau and amyloid pathology on neuroinflamma-
tion, we quantified the protein levels of IL-10, IL-1β, IL-2,
IL-5, IL-6, and TNF-α within the cortex (Fig. 3). In T5x
mice, a surprising three-fold decrease in IL-1β relative to
5xfAD mice was observed (p < 0.0001; Fig. 3). Interest-
ingly, IL-5, IL-6, and IL-10 levels were also decreased in
T5x mice compared to 5xfAD littermates (p < 0.05;
Fig. 3). In contrast, T5x mice showed an approximately
7-fold increase in both IL-2 and TNF-α compared to
wild-type and transgenic littermates (p < 0.0001). Be-
cause IL-2 and TNF-α levels highly correlate with PHF-
1 (Additional file 3: Figure S3, IL-2: PHF-1 R2 = 0.481,
TNF-α: PHF-1 R2 = 0.557), this suggests that increasing
tau pathology likely plays a role in the induction of
these cytokines. Whereas IL-2 and TNF-α promotes
microglial activation and proliferation, IL-10 has been
shown to inhibit microglial Aβ phagocytosis [19, 29, 57,
89]. Taken together, the cytokine profile of T5x mice
suggested that microglial function might be differen-
tially affected by varying amounts of tau and amyloid
(See figure on previous page.)
Fig. 2 Hippocampal tau hyperphosphorylation is greatly increased by concurrent beta-amyloid pathology. Western blot and immunofluorescent
analysis was used to examine the effects of concurrent Aβ and tau pathology on tau accumulation, phosphorylation, and solubility. Examination
of the soluble fraction of microdissected hippocampi (a), revealed an electrophoretic shift in total human tau (HT7) to produce a second band at
65 kDa, likely representing hyperphosphorylation of tau (p = 0.0007), but no significant change in the unphosphorylated band at 60 kDa (p = 0.71).
Western blotting for several tau phosphoepitopes revealed similar 60 and 60 kDa bands. In this case, as both bands represent phosphoryalation
of that epitope, quantification was performed on the combined bands. While phosphorylation at Ser199 and Ser202 was unchanged between
Thy-Tau22 and T5x mice, several other pathological phospho-epitopes including AT100 (p = 0.0002), AT270 (p = 0.0002), and PHF1 (p = 0.003)
exhibited robust 2–4 fold increases in T5x hippocampal fractions versus Thy-Tau22 lysates (b). Whereas total levels of insoluble human tau (HT7)
and Ser199 and Ser202 epitopes were unchanged between T5x and Thy-Tau22 mice, T5x mice exhibited dramatic 7–10 fold increases of insoluble
AT100, AT270, and PHF1 phosphorylated tau (p < 0.0001). Representative immunohistochemical labeling of AT8 (c) and PHF1 (d) immunoreactive
tangles in the hippocampus further illustrate the enhancement of tau hyperphosphorylation induced by Aβ pathology in T5x mice. Labeling for
the tau conformational epitope MC1 at both low (e) and high (f) power magnification likewise reveals a large increase in MC-1 immunoreactive
CA1 neurons (quantification shown in Additional file 2: Figure S2). Data are represented as mean ± SEM, normalized to % of WT group, n ≥ 8
mice/group. * Indicates p < 0.05 for both ANOVA and Fisher’s protected least-significant difference (PLSD) post hoc tests with significance versus
all other groups, whereas *over a bar indicates significance between 2 or 3 particular groups. Scale Bar = 100 μm in (c-e) and 50 μm in (f)
Fig. 3 The combination of Aβ and tau pathology alters the production of cytokines within the brain. MSD multiplex ELISA was utilized to examine
several key cytokines. Compared to WT, Tau and 5xfAD littermates, T5x mice showed a significant increase in both TNF-α and IL-2 (p < 0.0001). In
contrast, T5x mice exhibited a significant decrease in IL-1β in comparison to 5xfAD littermates (p < 0.0001) as well as decreases in IL-5, IL-6, and IL-10
(p < 0.05). Data are represented as mean ± SEM, n≥ 8 mice/group. * Indicates p < 0.05 for both ANOVA and Fisher’s protected least-significant
difference (PLSD) post hoc tests with significance versus all other groups, whereas *over a bar indicates significance between 2 or 3 particular groups
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and led us to investigate whether microglia number or
activation state were also altered in T5x mice.
Tau and Aβ synergistically modulate astrocyte and
microglia number and morphology
To determine whether neuroinflammatory changes in
T5x mice were associated with astrogliosis, astrocyte
morphology was examined in all genotypes (Additional
file 4: Figure S4A). Astrocyte total volume, as assessed
by GFAP immunoreactivity, was increased 2–3 fold in
T5x mice compared to 5xfAD and Thy-Tau22 litter-
mates within CA1 and the cortex (Additional file 4:
Figure S4B, ANOVA and PLSD p < 0.05). Western blot
analysis of cortical fractions further corroborated these
results revealing an approximately two-fold increase in
GFAP protein levels in T5x lysates (Additional file 4:
Figure S4C, ANOVA and PLSD p < 0.05). This increase
in astrogliosis is suggestive of a synergistic immune re-
sponse to the combination of tau and beta-amyloid
pathology in T5x mice.
Next, we sought to determine the effect of amyloid and
tau on microgliosis as microglia are considered the pre-
dominant immune cells of the brain, are tasked with the
bulk phagocytosis of CNS material including beta-
amyloid, and are known to play a prominent role in AD
pathogenesis [1, 48, 50, 64]. To investigate how microglia
are affected by AD pathology in T5x mice, we quantified
microglial number and characterized their morphology
within the CA1, the dentate gyrus (DG), and the parietal
association cortex (PAC) from all four genotypes (Fig. 4a,
b, c, respectively). Our analysis revealed a more than two-
fold increase in the number of microglia (IBA1+) within
T5x mice compared to the other genotypes in CA1 (p <
0.0001) and this increase was similarly observed within
the DG and PAC (Fig. 4a, d). Activated pro-inflammatory
microglia are typified by short processes and decreased
branching [60]. In T5x mice, microglia process length per
microglia was significantly decreased compared to all
other genotypes, in all three analyzed regions: CA1, DG,
and PAC (Fig. 4e, ANOVA and PLSD p < 0.05). T5x mice
also displayed significant decreases in microglial branch-
ing per microglia compared to all genotypes, in each of
the same three brain regions (Fig. 4 f, ANOVA and PLSD,
p < 0.05). 5xfAD microglia also exhibited significantly
shorter processes and decreased branching compared to
WT and Thy-Tau22 in PAC and DG, supporting previous
studies demonstrating that amyloid accumulation can
drive microglia activation [12, 55]. However, T5x microglia
exhibited shorter processes and less process branching in
CA1 relative to their age-matched 5xfAD counterparts-
suggesting that tau plays a synergistic role with amyloid in
the modulation of microglia activation state and that the
dramatic increase in tau pathology in T5x mice further ex-
acerbates microgliosis.
Additional evidence of tau-mediated microglial activa-
tion was observed by examination of the morphology of
microglial populations within CA1 of the hippocampus-an
area that exhibits abundant tauopathy [16, 72]. T5x brain
sections labeled for Beta-III tubulin (B3T) and IBA1 re-
vealed a distinct microglia population uniquely surround-
ing the dendrites of pyramidal neurons (Fig. 4h-k). These
microglia are characterized by long rod-like morphology
with shortened processes and were observed in T5x mice
but not 5xfAD, Thy-Tau22, or WT littermates (Fig. 4a).
Rod-shaped microglia of similar morphology have recently
been reported to accumulate in areas of acute neuronal
injury and axonal degeneration, further supporting the
notion that accumulating tau pathology further alters
microglial activation in T5x mice [82, 87].
Amyloid plaque burden is significantly reduced in T5x
mice versus 5xfAD littermates
Although the effects of amyloid on tau hyperphosphor-
ylation have been extensively studied, far fewer reports
have examined whether tau pathology could potentially
influence amyloid burden. While we hypothesized that
no differences in Aβ plaque pathology would be de-
tected between T5x and 5xfAD littermates, changes in
microgliosis suggested that microglial interactions with
Aβ could potentially be altered. We therefore examined
Aβ plaque load using IMARIS 3-D volumetric quantifi-
cation. Surprisingly, this analysis revealed a ~50 % re-
duction in Aβ plaque volume within multiple brain
regions of T5x versus 5xfAD mice (Fig. 5a-b, p < 0.05).
Amyloid plaque deposition was significantly lower in
the CA1 of the hippocampus, the retrosplenial cortex
(RC), and parietal association cortex (PAC) of T5x ver-
sus 5xfAD littermates (ANOVA and PSLD p < 0.05).
Within the dentate gyrus of the hippocampus, T5x mice
exhibited a non-significant trend towards decreased plaque
volume (p = 0.07, Fig. 5b).
To examine whether the decrease in amyloid burden re-
sulted from a down-regulation of the APP transgene, APP
soluble protein levels were quantified by Western blot
analysis in both the cortex (Fig. 5c-e) and hippocampus
(data not shown). Our results revealed no changes in APP
holoprotein (p = 0.81) and also no change in C99, the C-
terminal fragment produced by beta-secretase cleavage of
APP (p = 0.86) between T5x and 5xfAD littermates. To
determine whether alterations in Aβ might be influenced
by changes in endogenous amyloidogenic enzymes we also
examined the mRNA expression of BACE1, BACE2,
ADAM10, PSEN1, and PSEN2 and found no significant
differences across genotypes (Additional file 5: Figure S5).
These data therefore support the notion that changes in
Aβ load may be mediated by alterations in Aβ clearance
mechanisms, rather than altered Aβ production.
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To further validate the observed effects on Aβ plaque
load we used a Mesoscale Discovery (MSD) V-Plex Aβ
Peptide ELISA to quantify both soluble and insoluble
levels of Aβ38, Aβ40, and Aβ42. MSD analysis of soluble
cortical fractions revealed no significant differences
between T5x and 5xfAD littermates for Aβ38 Aβ40, or
Aβ42, consistent with the notion that production of sol-
uble Aβ is unchanged (Fig. 5 f). In contrast, levels of insol-
uble Aβ that contribute to fibrillar Aβ plaques exhibited a
significant ~2-fold decrease in T5x Aβ 38 (p = 0.03), Aβ40
(p = 0.01) and Aβ42 (p = 0.02) versus 5xfAD mice (Fig. 6g).
Thus, in T5x mice, there is a surprising two-fold decrease
Fig. 5 T5x mice exhibit decreased amyloid burden compared to 5xfAD littermates. a Amyloid deposition was quantified using immunofluorescent
labeling of Aβ (82E1) followed by confocal Z-stack imaging and IMARIS bitplane software analysis within CA1 of the hippocampus (CA1) the dentate
gyrus (DG), retrosplenial cortex (RSC), and parietal association cortex (PAC). b Amyloid plaque volume was significantly decreased in T5x mice relative
to 5xfAD littermates in CA1 (p = 0.03), RSC (p = 0.04), and the PAC (0.03), whereas a nonsignificant reduction was observed in the dentate gyrus
(p = 0.07). c To determine whether the observed reduction in Aβ pathology resulted from a change in APP transgene expression, human full-
length APP (6E10; ~100 kDA) and C99 (6E10; ~13 kDA) was examined and quantified by western blot, revealing no differences between T5x
and 5xfAD groups (d, e). Next, levels of soluble and insoluble Aβ38, 40 and 42 were examined using a Mesoscale Devices (MSD) multiplex ELISA.
Interestingly, while soluble levels of Aβ where unchanged between T5x and 5xfAD groups (f), levels of insoluble Aβ38, 40 and 42 were significantly
decreased in T5x mice relative to 5xfAD littermates (g). Data are represented as mean ± SEM, n ≥ 9 mice/group. * indicates p < 0.05 for both
ANOVA and Fisher’s protected least-significant difference (PLSD) post hoc tests between T5x and 5x groups for that brain region or Aβ species.
Scale Bar = 50 μm
(See figure on previous page.)
Fig. 4 Microglial number and morphology is dramatically altered in T5x mice. Microglia were immunohistochemically labeled with IBA1 and then
quantified by IMARIS bitplane analysis of confocal Z-stacks to determine the effects of Aβ, and tau pathology on microglial number and
morphology. Analysis was performed within the CA1 (a) and dentate gyrus (b) of the hippocampus and the parietal association cortex (c), revealing
a significant 2–3 fold increase in microglial number in T5x versus WT mice in each of these regions (p < 0.0001). T5x mice exhibited a similar
2-fold increase in microglial number relative to Thy-Tau22 mice in all 3 regions (d). Within CA1, T5x microglial number was also substantial
higher than 5xfAD littermates (p < 0.0001). However, T5x mice exhibited a more subtle increase in comparison to 5xfAD mice within the dentate
gyrus (p = 0.02) and cortex (p = 0.07). e Automated quantification of microglial process length (e) and branching (f) also revealed several significant
differences withT5x microglia exhibit significantly shorter process length and decreased microglial branching compared to all other genotypes in CA1
(p < 0.01) and to Thy-Tau22 and WT groups within the dentate gyrus and cortex, (p < 0.05). h-k Examination of microglia in hippocampus CA1 revealed
a unique population of rod-like microglia in T5x mice. β3-tubulin immunoreactivity (green, g) were associated with a microglial response, IBA-1 labeled
microglia (red, h) were imaged within the stratum radiatum. Interestingly, this examination revealed a very specific pattern of microglial morphology
within T5x mice that was not present in any of the other three genotypes. The appearance of elongated, linearly organized microglia is reminiscent of
highly activated ‘rod-like’ microglia that are found in association with neurodegenerative changes [11, 87]. Thus, the microglia appear to mount a very
specific response to hippocampal dendritic degeneration within T5x mice. Data are represented as mean ± SEM, n≥ 8 mice/group. * Indicates p < 0.05
for both ANOVA and Fisher’s protected least-significant difference (PLSD) post hoc tests with significance versus all other groups, whereas *over a bar
indicates significance between 2 or 3 particular groups. Scale Bar = 100 μm in (a-c), 30 μm in (g-i), and 10 μm in (j)
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in insoluble Aβ species and total plaque volume when
compared to 5xfAD littermates.
T5x microglia exhibit increased Aβ phagocytosis
While greater microglial numbers alone could poten-
tially promote Aβ clearance, the observed changes in
T5x microglial morphology and decreased brain IL-10
levels might also indicate increased microglial phago-
cytic capacity that could further contribute to Aβ reduc-
tion. Altered brain cytokine profiles indicate changes in
microglia activation state, which can influence amyloid
phagocytosis [23, 68]. For example, decreased IL-10 levels
is associated with increased microglial Aβ phagocytosis
[40, 54]. To test the hypothesis that reduced Aβ in T5x
mice is the result of increased phagocytic capacity of T5x
microglia, microglial Aβ internalization was assessed using
volumetric IMARIS analysis in matching brain sections of
T5x and 5xfAD mice. Microglia were identified by IBA1
immunoreactivity and Aβ phagocytosis was determined
by co-localization of Aβ (82E1) and CD68 which is only
present in microglial phagolysosomes (Fig. 6a). While the
total volume of phagolysosome labeling per microglia was
not significantly different between 5xfAD and T5x litter-
mates (Fig. 6b, p = 0.18), quantification of the proportion
of Aβ internalized within CD68+ phagolysosomes was sig-
nificantly different between T5x and 5xfAD groups. In
fact, this analysis revealed a nearly 30 % increase in the
ability of T5x microglia to internalize Aβ versus 5xfAD lit-
termates (Fig. 6c, p = 0.01). Taken together, these data
sug\gest that increases in tau pathology and neuroinflam-
mation can affect microglial Aβ phagocytosis, leading to a
profound increase in amyloid clearance and reduction of
plaque load in T5x mice.
Discussion
Although the notion that amyloid increases tau pathology
is well established, very few studies have in contrast exam-
ined whether a reciprocal relationship between tau and
the development of amyloid pathology might exist. Begin-
ning in 2001, two seminal studies demonstrated that Aβ
could exacerbate the development of tau pathology in
transgenic AD tau models [24, 47]. Subsequently, a similar
causal relationship between Aβ and tau pathology was
established in several other AD models [13, 17, 39, 62].
Even in the absence of the expression of a human tau
transgene, many AD transgenic mice exhibit some degree
of Aβ-induced tau hyperphosphorylation, a prerequisite
for the development of neurofibrillary tangles. Likewise, in
humans, triplication of APP, either in some family pedi-
grees or in trisomy 21, leads to elevated levels of Aβ and
the development of tau pathology [53, 79]. Independent of
Aβ, alterations in Presenilin-1 have also been shown to
increase tau hyperphosphorylation in transgenic mice
expressing mutant tau [14, 78]. Thus, it is quite likely that
the presence of a mutant PS1 transgene in 5xfAD influ-
ences tau phosphorylation both directly and indirectly by
enhancing Aβ42 generation.
As expected, the accumulation of Aβ in T5x mice
leads to a dramatic increase in tau hyperphosphorylation
and increased accumulation of neurofibrillary tangle
pathology within the hippocampus and neocortex. Yet
surprisingly, T5x mice also exhibited a 50 % reduction in
amyloid plaque burden and insoluble Aβ species versus
5xfAD littermates. Although the expression of both the
APP and tau transgenes are driven by the Thy1 promoter,
the expression of APP in T5x mice was unchanged and
therefore, decreased Aβ levels were not the result of
Fig. 6 T5x microglia phagocytose more Aβ than their 5xfAD counterparts. (a) Equivalent 7 month old T5x and 5xfAD sections were labeled for
microglia (IBA1, green), Aβ (82E1, red), and microglial phagolysosomes (CD68, blue). IMARIS bitplane software rendering of confocal Z-stacks was
then used to calculate the volume of phagolysosomes within microglia and then the volume of internalized Aβ within those CD68+ microglial
phagolysosomses, depicted in greyscale in A. Together, this analysis demonstrate that although T5x and 5xfAD microglia exhibit no differences in
phagolysosome volume per microglia (b), the amount of Aβ within the phagolysosomes of T5x microglia was significantly increased (c) versus
5xfAD microglia. Data are represented as mean ± SEM, normalized to % of 5xfAD group, n ≥ 9 mice/group. * Indicates p < 0.05 for both ANOVA
and Fisher’s protected least-significant difference (PLSD) post hoc tests. Scale Bar = 20 μm
Chen et al. Acta Neuropathologica Communications  (2016) 4:63 Page 10 of 15
altered transgene expression. Furthermore, levels of sol-
uble Aβ and APP processing enzymes were unaffected;
suggesting that the observed decreases in plaques and
insoluble Aβ was not due to effects on APP processing.
However, the combination of amyloid and tau pathology
did produce a dramatic effect on neuroinflammatory pro-
cesses, included increased microgliosis and astrogliosis in
T5x versus 5xfAD or Thy-Tau22 littermates. Therefore,
we examined whether changes in specific cytokines could
explain the increase in neuroinflammation. Our data show
that the combined presence of amyloid and tau pathology
exacerbates the levels of both TNF-α and IL-2 (Fig. 4). In
contrast, the observed decreases in IL-1β, IL-5, and IL-6
in T5x mice versus 5xfAD littermates may reflect the
predominant influence of amyloid on the release and mat-
uration of certain pro-inflammatory cytokines. Although
IL-1β has been shown to increase tau phosphorylation,
amyloid has also been reported to promote astrocytic and
microglial release of IL-1β [20, 36, 40, 74]. Thus, while
one may expect elevated IL-1β in T5x mice in association
with increased tau hyperphosphorylation [49], the influ-
ence of reduced amyloid burden on IL1β induction may
take precedence over effects caused by changes in tau.
Therefore, it may be the case that IL-1β, IL-5 and IL-6 are
less elevated in T5x than 5xfAD mice as a consequence,
rather than a cause of reduced amyloid burden. However,
future studies that examine the progression of pathology
and inflammation in T5x across multiple ages will likely
help to resolve these questions.
TNF-α, a pro-inflammatory cytokine that is released by
activated microglia was one of the most upregulated cyto-
kines observed in T5x mice [41, 55]. Although TNF-α
does not directly increase microglial proliferation, TNF-α
promotes astrocyte proliferation and GM-CSF release,
which in turn, can stimulate microglial proliferation [6,
45, 73]. Taken together, elevated astrocyte numbers and a
~5-fold increase in TNF-α in T5x mice relative to 5xfAD
and Thy-Tau22 littermates suggests that the combined
stress of amyloid and tau pathology work synergistically to
promote both astrocytic and microglial proliferation. Fur-
thermore, the significant decrease in IL-10 expression in
T5x mice suggested that microglial phagocytosis of Aβ
may also be altered as recent studies have shown that de-
letion of IL-10 can enhance microglial Aβ phagocytosis
[29]. Our finding that T5x mice exhibit a similar decrease
in IL-10 relative to Thy-Tau22 and 5xFAD littermates sug-
gest that decreased IL-10 is a result of the combined stress
of tau and amyloid pathology. Subsequent analysis con-
firmed that T5x microglia indeed have increased Aβ
phagocytosis, providing further support that tau pathology
contributes to microglial regulation of amyloid. It should
be noted that while our results support strong interac-
tions between tau pathology and microglial activation,
the exact temporal relationship between the two is still
to be determined. Additional longitudinal studies will
be needed to determine whether accumulation of tau
pathology first promotes microglial activation or
whether changes in microglia precede and drive in-
creases in tau hyperphosphorylation.
While cytokines are often determined by the extent of
AD pathology, they can also control the progression of
the disease through the modulation of microglial re-
sponse. The influence of microglia in AD has received
growing attention with the recent discovery of genetic
risk polymorphisms in several microglial-enriched genes
[15]. Some of these risk factor genes such as CD33 have
themselves been implicated in microglial Aβ phagocyt-
osis [25, 81]. Thus, the role of microglia in limiting Aβ
pathology continues to garner new attention. Microglia
have long been implicated in the modulation of tau
hyperphosphorylation and misfolding through cytokine-
mediated neuroinflammatory activation of tau kinases
[49, 84]. More recently, studies have shown that the mis-
folding of tau can promote microglial activation [88],
and tau oligomers and fibrils have been found to interact
directly with microglia [56]. In addition, microglia have
also recently been implicated in the propagation of tau
within the brain [4]. The fact that microglia exhibit the
capacity to directly phagocytose the same tau oligomers
that can promote their activation, highlights the possibil-
ity that tau pathology is not only exacerbated by micro-
glial activation, but likely in turn modulates microglial
responses within the brain [52]. We reasoned that changes
in cytokine levels observed in T5x mice would affect
microgliosis and our current findings suggest that tau and
amyloid pathology in T5x mice synergistically recruit a ro-
bust microglial response. Significantly increased activated
amoeboid microglia in T5x mice versus Thy-Tau22 litter-
mates suggests that amyloid pathology is the strongest
determinant of microglial activation. Amyloid holds an ad-
vantage over predominately intracellular tau aggregates in
its potential influence over microglial activation as evident
of amyloid soluble oligomers released from abundant
extracellular plaques [55, 70, 77]. However, our findings of
increased microglial activation, phagocytosis, and num-
bers in T5x mice, suggest that tau pathology can also con-
tribute to or further modulate microglia activation state.
The remaining question is exactly how development of
tau pathology influences the neuroinflammatory response.
One possibility is that amyloid driven tau hyperphosphor-
ylation and subsequent release of intracellular factors and
tau oligomers from degenerating neurons leads to altered
microglial activation states, potentially increasing Aβ
phagocytosis and thereby providing a somewhat beneficial
response. Previous studies have reported the activation of
microglia by the release of apoptotic factors and intracel-
lular molecules such as ADP or ATP [21, 37, 58]. When
we examined T5x mice for dendritic degeneration, we
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observed a reduction in hippocampal Beta-III tubulin
staining in T5x mice compared to transgenic and WT
littermates (Additional file 6: Figure S6). Notably, hippo-
campal regions displaying the significant reduction in
Beta-III tubulin were accompanied by the previously de-
scribed rod microglia (Fig. 4 g-j) [80]. Although not exten-
sively characterized, rod microglia have been found in
human AD cases and exhibit abnormally frequent inter-
actions with synaptic clefts [46, 59, 82]. T5x rod-like
microglia are similar in morphology to recently de-
scribed rod-microglia which appear highly activated
and respond to diffuse neuronal injury [87]. The associ-
ation between reduced β3-Tubullin density and rod
microglia presence therefore suggests that degenerating
dendrites and subsequent release of intracellular factors
such as ADP may contribute to the altered microglia
activation state in T5x mice. However, further studies
are clearly needed to elucidate the exact mechanisms
by which tau synergizes with Aβ to modulate microglial
activation.
It is important to acknowledge that our findings both
corroborate and differ from other recently examined
amyloid-tau crosses. We report a significant reduction in
amyloid plaque burden and insoluble Aβ in T5x mice
relative to 5xfAD littermates that appears to be mediated
via increased microglial-mediated Aβ clearance. Using a
similar model, one group has shown that 5xfAD crossed
with Tg30 tau mice likewise exhibit decreased Aβ path-
ology, although the potential role of microglia in this
finding was not examined [35]. In contrast, two other
studies crossed 5xfAD mice with other tau models and
reported no change in Aβ plaques by optical densitom-
etry, although only 3 or 4 mice per group were com-
pared versus group sizes of 9–10 mice for the current
Aβ ELISA analysis [75]. Yet, one of these studies never-
theless showed a non-significant 45 % reduction in Aβ
plaque load at 3 months of age. It is therefore quite pos-
sible that the use of 3D plaque volume quantification,
ELISA, or a larger sample size would have revealed a simi-
lar significant reduction in Aβ to that observed in the
current study. In another study, Tg2576 APP mice were
crossed with mutant tau VLW mice. Surprisingly, this
study reported a significant increase in amyloid deposition
in bigenic mice [67]. Likewise, a recent study that exam-
ined a cross between rTgTauEC and APP/PS1 mice also
reported increased amyloid burden [66].
These varying reports suggest that perhaps the magni-
tude of tau pathology and/or microgliosis can influence
the effects on Aβ pathology. In support of this notion, we
find that T5x mice exhibit a dramatic increase in micro-
glial number, shift in morphology, and change in cytokines
that is not apparent in Thy-Tau22 littermates with lower
levels of tau pathology (Figs. 4 and 5). Interestingly, in
other studies that crossed different tau models with 5xfAD
mice [35, 75], there were either no significant changes or a
similar decrease in amyloid pathology. In contrast, one
study reported an increase in amyloid burden when
Tg2576 mice were crossed with VLW tau mice [67].
5xfAD mice, which carry three APP and two PS1 muta-
tions, generate considerably more amyloid pathology than
Tg2576 mice and the presence of a PS1 transgene may
further promote tau hyperphosphorylation both directly
[14, 78] and indirectly by enhancing Aβ42 generation.
Thus, differences in levels of tau, the type and magnitude
of amyloid pathology, and their corresponding effects on
microglial activation state might explain these discrepan-
cies. For example, it is quite possible that the more aggre-
gation prone Aβ42 leads to a greater increase in tau
pathology and a differential activation of microglia that
combine to promote microglial phagocytosis. Another
possible explanation for these contrasting findings is the
potential impact of background strain on pathology. In
the current study we crossed congenic C57/Bl6 5xfAD
mice with congenic C57/Bl6 Thy-Tau22 mice, thus back-
ground strain was identical between all four genotypes
examined. In some of the contrasting studies, the cross-
bred mice exhibited differential mixed background strains
that include Bl6, CH3, and FVB [66] and thus variability
in background genetics even between littermates could
influence the development of pathology. Although our
current data clearly suggests that tau pathology can reduce
the accumulation of Aβ, these prior reports that in many
cases corroborate our findings but in others contrast our
findings clearly suggest that this remains a highly complex
question that will need additional examination. For ex-
ample, it is quite possible that changes in APP trans-
port or alterations in autophagy also play a role in this
process and thus studies that further examine these
additional potential mechanisms are also needed.
Conclusion
In conclusion, we have established an AD model that
provides further insight into the potential reciprocal re-
lationships between amyloid, tau and neuroinflamma-
tion. The combination of these pathologies significantly
increases tau hyperphosphorylation and microgliosis,
yet decreases amyloid burden. Our data also suggest
that tau-induced increases in microglial number, and
phagocytic activity may explain the reductions in amyl-
oid burden. The changes observed in amyloid accumu-
lation and microgliosis in the presence of tau pathology
suggests that therapies targeting tauopathy could have
increased benefit towards treating additional underlying
proponents of AD. Therefore, our study adds to the
growing understanding of the role of microglia in AD
pathogenesis and suggests that differential activation of
these cells in response to Aβ and tau pathology can have
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both detrimental as well as beneficial effects on disease
progression.
Additional files
Additional file 1: Figure S1. Tau hyperphoshorylation within the cortex
is also increased by Aβ accumulation. (A) Although levels of soluble
unphosphorylated human tau (HT7 60 kDA, p = 0.19), p-S199, and p-S201
are not significantly different between T5x and Thy-Tau22 littermates,
phosphorylation of tau at the 65 kDA HT7 band and the combined
phosphorylation of both 60 and 65 kDa bands as detected with AT100,
AT270, and PHF1 pathological epitope antibodies is greatly increased
(p < 0.01). (B) Levels of insoluble human tau (HT7), p-S199, and p-S201
within the cortex are also unchanged, but again insoluble accumulation
of AT100, AT270, and PHF1 phosphorylated tau is dramatically elevated
in T5x mice (p < 0.0001). Immunohistochemical labeling of AT8 (C) and
PHF1 (D) in the cortex further demonstrate the considerable increase in
tau accumulation that occurs in T5x mice. Likewise cortical labeling of
MC1 at low (E) and high (F) magnification (quantified in Additional file
2: Figure S2) again reveal a significant increase in this pathological
conformational tau epitope. Data are represented as mean ± SEM,
normalized to % of WT group, n ≥ 8 mice/group. * Indicates p < 0.05 for
both ANOVA and Fisher’s protected least-significant difference (PLSD)
post hoc tests with significance versus all other groups, whereas *over
a bar indicates significance between 2 or 3 particular groups. Scale Bar
= 100 μm in C-E and 50 μm in F. (PDF 16547 kb)
Additional files 2: Figure S2. T5x mice exhibit increased levels of Tau
phosphorylation and misfolding. (A) The ratio of phosphorylated
human tau (65 kDa) to unphosphorylated human tau (60 kDa) was
quantified by western blot. Analysis revealed significantly higher 65:60 kDa
HT7 ratio in T5x mice relative to Tau22 littermates, suggesting that tau
hyperphosphorylation is exacerbated by the presence of Aβ in T5x
mice. (B) Equivalent hippocampal sections were examined from
7-month old T5x and Thy-Tau22 mice and immunohistochemically
labeled with the conformational-specific tau antibody; MC-1 (see Figs. 2
and 3). Quantification revealed a significant increase in the numbers of
MC-1-positive neurons in hippocampus CA1 (p < 0.0001) and an even
greater increase in MC-1-immunoreactive cells within the perirhinal/
entorhinal cortex. Data are represented as mean ± SEM of optical
density (O.D.), n ≥ 8 mice/group. * Indicates p < 0.05 for both ANOVA
and Fisher’s protected least-significant difference (PLSD) post hoc
tests. (PDF 427 kb)
Additional files 3: Figure S3. Changes in tau pathology correlate
closely with alterations in TNFα and IL-2. (A) Further demonstrating the
shift in cytokines that occurs in T5x mice, IL-6 and TNFα exhibit a bimodal
distribution, with high levels of TNF α but low levels of IL-6 in T5x mice
(green) versus low TNFα and high IL-6 in WT (purple), Thy-Tau22 (blue),
and 5xfAD (red) mice. (B) TNFα and IL-2 expression are very closely
correlated (R2 = 0.925) especially in T5x mice (green), illustrating a
strong concordance between these two pro-inflammatory cytokines.
Both soluble (C) and insoluble (D) measures of cortical PHF-1 tau
correlate well with cortical TNFα levels. Likewise, soluble (E) and
insoluble (F) measures of PHF-1 tau also correlate closely with IL-2
expression. (PDF 920 kb)
Additional files 4: Figure S4. T5x mice exhibit increased astrogliosis.
(A, B) Immunohistochemical analysis and IMARIS quantification of GFAP-
labeled astrocytes reveal elevated numbers within CA1 of the hippocampus
(WT p = 0.13; 5x p = 0.03; Tau p = 0.04) and the parietal association cortex
(WT, Tau p < 0.0001; 5x p = 0.0002), but no differences within the dentate
gyrus. (C) Western blot analysis of GFAP in cortical fractions corroborate
these findings by demonstrating a significant increase in GFAP between T5x
and both WT and Thy-Tau22 groups (WT p = 0.006; 5x p = 0.10; Tau p =
0.002). Data are represented as mean ± SEM of optical density (O.D.), n≥ 8
mice/group. * Indicates p < 0.05 for both ANOVA and Fisher’s protected
least-significant difference (PLSD) post hoc tests with significance versus all
other groups, whereas *over a bar indicates significance between 2 or 3
particular groups. Scale Bar = 100 μm. (PDF 11243 kb)
Additional files 5: Figure S5. Nanostring analysis reveals no differences
in mRNA expression of APP-processing enzymes. Hippocampal mRNA
was isolated from each genotype and examined using a custom Nanostring
panel to quantify APP-processing associated genes including murine APP,
BACE1, BACE2, ADAM10, PSEN1, and PSEN2. In each case, no differences
between genotype were observed. (PDF 433 kb)
Additional files 6: Figure S6. The combination of Aβ and Tau pathology
leads to reductions in hippocampal β3-tubulin. (A-D) To determine whether
T5x mice begin to exhibit early signs of neurodegeneration, dendritic
architecture was examined by β3-tubulin immunolabeling of all four
genotypes. (E-G) Quantification of β3-tubulin revealed a significant
reduction in T5x mice compared to WT and transgenic littermates within
the pyramidal cell layer (E; p < 0.05), stratum radiatum (F; p < 0.05), and
molecular layer (G; WT, Tau p < 0.05; 5x p = 0.27) of the hippocampus. Data
are represented as mean ± SEM of optical density (O.D.), n≥ 8 mice/group.
* Indicates p < 0.05 for both ANOVA and Fisher’s protected least-significant
difference (PLSD) post hoc tests with significance versus all other groups,
whereas *over a bar indicates significance between 2 or 3 particular groups.
Scale Bar = 100 μm in A-D, 30 μm in H-J, and 10 μm in K. (PDF 3896 kb)
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